Company Overview
Snapshot
Founded in March 2018 by Masanobu Ogawa, Doron Friedman, and Eran Perry, Follicle Pharma operates with 1–10 employees. The company has raised $5 million across one funding round, with Maruho Israel Innovation Fund as an investor. Follicle Pharma is currently in the clinical trial stage with its products FOL100 and FOL500.
Business overview
Follicle Pharma is a Health Tech & Life Sciences company focused on developing advanced therapeutics for follicular diseases. The company utilizes a proprietary technology platform and intellectual property derived from research into particle behavior in emulsions and hydrophobic active ingredients. This enables the creation of topical targeted delivery systems designed to overcome the challenges of intra-follicular delivery. Follicle Pharma operates within the pharmaceuticals, drug delivery, and dermatology sectors, serving the life sciences and healthcare industries.
Log in to access full profile ›Company Intelligence Q&A
- When was Follicle Pharma founded?
- Follicle Pharma was founded in March 2018.
- Who are the founders of Follicle Pharma?
- Follicle Pharma was founded by Masanobu Ogawa, Doron Friedman, and Eran Perry.
- What is Follicle Pharma's primary sector?
- Follicle Pharma's primary sector is Health Tech & Life Sciences.
- What is Follicle Pharma's core technology?
- Follicle Pharma's core technology involves a platform based on the research of particle behavior in emulsions and hydrophobic active ingredients, enabling targeted delivery systems for follicular diseases.
- What products are currently in clinical trial for Follicle Pharma?
- Follicle Pharma currently has products FOL100 and FOL500 in the clinical trial stage.